Search

Your search keyword '"Li, Kate"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Li, Kate" Remove constraint Author: "Li, Kate"
49 results on '"Li, Kate"'

Search Results

1. Health information technology to advance care in accountable care organizations: Implications for Medicare patients.

3. Building Mini-Categories in Product Networks

4. Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase

6. 131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML

7. Targeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment

8. 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes

9. Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AML

11. LKB1 suppresses growth and promotes the internalization of EGFR through the PIKFYVE lipid kinase

12. Application of the Key Characteristics of Carcinogens to Bisphenol A.

14. Hospitalists staffing levels and hospital performance

20. AML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial

21. Long-Term Follow-Up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial

22. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.

23. Analysis of GEFS-Aerosols annual budget to better understand the aerosol predictions simulated in the model.

24. COVID-19 Provider Relief Funds Distribution by Hospital Characteristics.

29. Managing trade-in programs based on product characteristics and customer heterogeneity in business-to-business markets

30. 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

31. 131I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

32. High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

34. Response to “Comment on Coumarin Hazard Identification”

36. The interaction between high-level electronic medical record adoption and hospitalist staffing levels: A focus on value-based purchasing.

37. Supplemental Material, Coumarin_IJT_supplementary - Cancer Hazard Identification Integrating Human Variability: The Case of Coumarin

42. Sustainers: Hospitals with sustained superior performance.

43. Hospitalists staffing levels and hospital performance.

45. On the unsupervised analysis of domain-specific Chinese texts.

47. Bayesian Inference for Assessing Effects of Email Marketing Campaigns

48. Determinants of Sustained Superior Hospital Performance.

49. LKB1 suppresses growth and promotes the internalization of EGFR through the PIKFYVE lipid kinase.

Catalog

Books, media, physical & digital resources